Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?
Apr 11
Have your own idea? Try our Stock Screener
South Korean (KOSPI) Life Sciences Industry Analysis
UpdatedApr 17, 2025
DataAggregated Company Financials
Companies30
- 7D4.6%
- 3M-0.9%
- 1Y37.0%
- YTD9.9%
The Life Sciences industry is up 4.6% in the last week, with Samsung BiologicsLtd up 3.1%. Meanwhile, FutureChemLtd actually underperformed within the industry, shrinking 10% in the last week. In the last 12 months, the industry was up 37%. Earnings are forecast to grow by 18% annually.
Industry Valuation and Performance
Has the South Korean Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 18 Apr 2025 | ₩82.5t | ₩5.2t | ₩1.0t | 18.1x | 80.2x | 15.8x |
| Sun, 16 Mar 2025 | ₩83.0t | ₩5.2t | ₩999.9b | 10.4x | 83x | 16x |
| Tue, 11 Feb 2025 | ₩89.8t | ₩5.0t | ₩965.6b | 12.9x | 93x | 17.9x |
| Thu, 09 Jan 2025 | ₩81.0t | ₩5.0t | ₩965.6b | 13.4x | 83.9x | 16.2x |
| Sat, 07 Dec 2024 | ₩76.3t | ₩5.0t | ₩947.9b | 12.3x | 80.5x | 15.1x |
| Mon, 04 Nov 2024 | ₩79.7t | ₩4.8t | ₩885.3b | 13.1x | 90x | 16.4x |
| Wed, 02 Oct 2024 | ₩76.8t | ₩4.8t | ₩885.3b | 14.3x | 86.8x | 15.8x |
| Fri, 30 Aug 2024 | ₩74.9t | ₩4.8t | ₩887.7b | 16x | 84.4x | 15.5x |
| Sun, 28 Jul 2024 | ₩72.2t | ₩4.5t | ₩731.7b | 18.4x | 98.6x | 15.9x |
| Tue, 25 Jun 2024 | ₩58.2t | ₩4.6t | ₩691.8b | 18.1x | 84.2x | 12.6x |
| Thu, 23 May 2024 | ₩61.0t | ₩4.4t | ₩663.4b | 20.1x | 92x | 13.9x |
| Sat, 20 Apr 2024 | ₩62.6t | ₩4.7t | ₩654.7b | 18.7x | 95.7x | 13.4x |
| Mon, 18 Mar 2024 | ₩65.3t | ₩4.6t | ₩636.6b | 28.9x | 102.5x | 14.1x |
| Wed, 14 Feb 2024 | ₩65.3t | ₩4.5t | ₩714.4b | 33.8x | 91.4x | 14.4x |
| Fri, 12 Jan 2024 | ₩59.5t | ₩4.5t | ₩721.5b | 32.3x | 82.4x | 13.1x |
| Sun, 10 Dec 2023 | ₩56.5t | ₩4.5t | ₩721.6b | 31.8x | 78.2x | 12.4x |
| Tue, 07 Nov 2023 | ₩57.4t | ₩4.4t | ₩660.9b | 23.5x | 86.9x | 13.1x |
| Thu, 05 Oct 2023 | ₩54.3t | ₩4.4t | ₩660.9b | 27.6x | 82.1x | 12.3x |
| Sat, 02 Sep 2023 | ₩58.1t | ₩4.4t | ₩660.5b | 24.2x | 88x | 13.2x |
| Mon, 31 Jul 2023 | ₩60.9t | ₩4.2t | ₩673.4b | 27.6x | 90.4x | 14.5x |
| Wed, 28 Jun 2023 | ₩58.4t | ₩4.2t | ₩666.5b | 29.4x | 87.6x | 13.7x |
| Fri, 26 May 2023 | ₩62.0t | ₩4.3t | ₩611.6b | 31.3x | 101.4x | 14.5x |
| Sun, 23 Apr 2023 | ₩61.4t | ₩4.1t | ₩626.3b | 28.5x | 98x | 15x |
| Tue, 21 Mar 2023 | ₩63.2t | ₩4.0t | ₩714.1b | 26.7x | 88.4x | 15.8x |
| Thu, 16 Feb 2023 | ₩61.9t | ₩3.5t | ₩427.8b | 20.2x | 144.7x | 17.8x |
| Sat, 14 Jan 2023 | ₩63.3t | ₩3.4t | ₩428.7b | 19.8x | 147.5x | 18.4x |
| Mon, 12 Dec 2022 | ₩64.5t | ₩3.4t | ₩428.7b | 19.6x | 150.5x | 18.8x |
| Wed, 09 Nov 2022 | ₩68.0t | ₩3.0t | ₩448.5b | 23.3x | 151.6x | 22.8x |
| Fri, 07 Oct 2022 | ₩63.3t | ₩3.0t | ₩448.5b | 23x | 141.2x | 21.2x |
| Sun, 04 Sep 2022 | ₩65.9t | ₩3.0t | ₩448.7b | 22.1x | 146.9x | 22.1x |
| Tue, 02 Aug 2022 | ₩69.2t | ₩2.7t | ₩454.7b | 28.1x | 152.2x | 25.5x |
| Thu, 30 Jun 2022 | ₩63.2t | ₩2.7t | ₩454.7b | 28.5x | 138.9x | 23.3x |
| Sat, 28 May 2022 | ₩66.1t | ₩2.7t | ₩465.8b | 26.5x | 142x | 24.7x |
| Mon, 25 Apr 2022 | ₩59.6t | ₩2.4t | ₩379.4b | 24.5x | 157x | 24.6x |
Price to Earnings Ratio
157x
Current Industry PE
- Investors are pessimistic on the South Korean Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 80.2x which is lower than its 3-year average PE of 107x.
- The industry is trading close to its 3-year average PS ratio of 16.8x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have grown 39% per year over the last three years.
- Revenues for these companies have grown 29% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the South Korean Healthcare industry?
| KR Market | 6.94% | |
| Healthcare | 6.50% | |
| Life Sciences | 4.55% | |
| Clinical Research and Equipment | 4.55% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| A207940 Samsung BiologicsLtd | ₩1.06m | 3.9% +₩2.8t | 34.1% | PE69.6x | |
| A087010 Peptron | ₩162.20k | 28.0% +₩827.1b | 505.2% | PS1198.8x | |
| A141080 LigaChem Biosciences | ₩106.30k | 6.7% +₩243.1b | 71.2% | PE494.5x | |
| A445680 Curiox Biosystems | ₩23.10k | 19.4% +₩60.6b | -5.1% | PS81.2x | |
| A456070 ENCell | ₩14.54k | 7.7% +₩11.2b | n/a | n/a |
